LLY

1,031.85

-1.94%↓

JNJ

244.39

-0.83%↓

ABBV

228.56

+0.18%↑

NVS

167.5

+0.02%↑

MRK

122.86

-0.94%↓

LLY

1,031.85

-1.94%↓

JNJ

244.39

-0.83%↓

ABBV

228.56

+0.18%↑

NVS

167.5

+0.02%↑

MRK

122.86

-0.94%↓

LLY

1,031.85

-1.94%↓

JNJ

244.39

-0.83%↓

ABBV

228.56

+0.18%↑

NVS

167.5

+0.02%↑

MRK

122.86

-0.94%↓

LLY

1,031.85

-1.94%↓

JNJ

244.39

-0.83%↓

ABBV

228.56

+0.18%↑

NVS

167.5

+0.02%↑

MRK

122.86

-0.94%↓

LLY

1,031.85

-1.94%↓

JNJ

244.39

-0.83%↓

ABBV

228.56

+0.18%↑

NVS

167.5

+0.02%↑

MRK

122.86

-0.94%↓

Search

Inmode Ltd

Atidarymo kaina

SektoriusSveikatos priežiūra

13.99 -0.21

Apžvalga

Akcijų kainos pasikeitimas

24 val.

Dabar

Min

13.91

Max

14.12

Pagrindiniai rodikliai

By Trading Economics

Pajamos

5.2M

27M

Pardavimai

11M

104M

P/E

Sektoriaus vid.

9.93

108.767

Pelnas, tenkantis vienai akcijai

0.38

Pelno marža

26.022

Darbuotojai

660

EBITDA

5.7M

31M

Rekomendacijos

By TipRanks

Rekomendacijos

Neutralu

12 mėnesių prognozė

+24.44% upside

Dividendai

By Dow Jones

Kitas uždarbis

2026-04-27

Rinkos statistika

By TradingEconomics

Rinkos kapitalizacija

-126M

900M

Ankstesnė atidarymo kaina

14.2

Ankstesnė uždarymo kaina

13.99

Naujienos nuotaikos

By Acuity

50%

50%

161 / 351 reitingas Healthcare

Techninis įvertinimas

By Trading Central

Pasitikėjimas

Bearish Evidence

Inmode Ltd Grafikas

Ankstesni rezultatai nėra patikimas būsimų rezultatų rodiklis.

Susijusios naujienos

2026-02-24 23:07; UTC

Uždarbis

Woolworths 1st Half Profit Hit By Worker Pay Dispute, Still Boosts Dividend

2026-02-24 23:01; UTC

Uždarbis

Fortescue 1st Half Net Profit, Dividend Rise on Higher Shipments, Prices -- Update

2026-02-24 22:59; UTC

Uždarbis

WiseTech to Cut 2,000 Jobs as It Asks AI to Boost Profitability -- Update

2026-02-24 22:42; UTC

Uždarbis

WiseTech to Cut 2,000 Jobs as It Asks AI to Boost Profitability

2026-02-24 22:24; UTC

Įsigijimai, susijungimai, perėmimai

Warner Bros. Discovery Board Says Paramount Skydance's New Proposal Could Top Netflix Agreement -- Update

2026-02-24 23:46; UTC

Rinkos pokalbiai

Gold Edges Higher Amid Possible Position Adjustments -- Market Talk

2026-02-24 23:36; UTC

Rinkos pokalbiai

Nikkei May Rise, Tracking Wall Street's Rebound -- Market Talk

2026-02-24 23:30; UTC

Rinkos pokalbiai

Fortescue's Copper Bet Is Long Term, While Iron Ore Remains Near-Term Driver -- Market Talk

2026-02-24 23:20; UTC

Rinkos pokalbiai

Fortescue Dividend Beat Overshadows Profit Miss -- Market Talk

2026-02-24 23:20; UTC

Rinkos pokalbiai

Global Equities Roundup: Market Talk

2026-02-24 23:16; UTC

Uždarbis

Oversea-Chinese Banking Corp.'s CEO: "Looking Ahead, We Remain Cautious Yet Positive">O39.SG

2026-02-24 23:13; UTC

Uždarbis

Oversea-Chinese Banking Corp. FY25 Non-Interest Income S$5.46B Vs. S$4.72B >O39.SG

2026-02-24 23:12; UTC

Uždarbis

Oversea-Chinese Banking Corp.: FY25 Net Interest Income S$9.15B Vs. S$9.76B>O39.SG

2026-02-24 23:10; UTC

Uždarbis

Oversea-Chinese Banking Corp. FY25 NPL Ratio 0.9%, Unchanged on Year>O39.SG

2026-02-24 23:10; UTC

Uždarbis

Oversea-Chinese Banking Corp. FY25 Net Interest Margin 1.91%, Down 29bps on Year>O39.SG

2026-02-24 23:08; UTC

Uždarbis

Oversea-Chinese Banking Corp. FY25 Net S$7.42B Vs. Net S$7.59B >O39.SG

2026-02-24 23:07; UTC

Uždarbis

Oversea-Chinese Banking Corp. FY25 Total Income S$14.61B Vs. S$14.47B>O39.SG

2026-02-24 22:52; UTC

Uždarbis

Woolworths 1H Profit Hit By Worker Pay Dispute, Still Boosts Dividend

2026-02-24 22:46; UTC

Uždarbis

Fortescue 1H Net Profit, Dividend Rise on Higher Shipments, Prices -- Update

2026-02-24 22:31; UTC

Įsigijimai, susijungimai, perėmimai

Warner Receives New Bid From Paramount -- 3rd Update

2026-02-24 22:29; UTC

Uždarbis

Woolworths: FY Ebit Growth for Australian Food Expected at Upper End of Mid-to-High Single Digit Range Provided in August

2026-02-24 22:28; UTC

Uždarbis

Woolworths: Australian Food Current Growth Rates Reflect Some Benefit from Cycling of Industrial Action Impacts

2026-02-24 22:27; UTC

Uždarbis

Woolworths: Australian Food Sales +7.2% Excluding Tobacco in 2H First Seven Weeks

2026-02-24 22:27; UTC

Uždarbis

Woolworths: Australian Food Sales +5.8% in 2H First Seven Weeks

2026-02-24 22:25; UTC

Uždarbis

Woolworths: Customers Continue to be Value-Focused, Shopping Multiple Retailers in Highly Competitive Environment

2026-02-24 22:24; UTC

Uždarbis

Woolworths: Trading in 3Q to Date Has Been Strong in Australian Food

2026-02-24 22:23; UTC

Uždarbis

Woolworths 1H Group Sales A$37.1 Bln, Up 3.4%

2026-02-24 22:22; UTC

Uždarbis

Woolworths Interim Dividend 45 Australian Cents/Share

2026-02-24 22:22; UTC

Uždarbis

Woolworths 1H Profit Before Significant Items A$859 Mln, Up 16.4%

2026-02-24 22:21; UTC

Uždarbis

Woolworths 1H Statutory Net Profit A$374 Mln, Down 49.4%

Akcijų palyginimas

Kainos pokytis

Inmode Ltd Prognozė

Kainos tikslas

By TipRanks

24.44% į viršų

12 mėnesių prognozė

Vidutinis 17.67 USD  24.44%

Aukščiausias 21 USD

Žemiausias 15 USD

Remiantis 5 „Wall Street“ analitikais, siūlančiais 12 mėnesių tikslines Inmode Ltd kainas – Dist per pastaruosius 3 mėnesius.

Bendras įvertinimas

By TipRanks

Neutralu

5 ratings

1

Pirkti

4

Laikyti

0

Parduoti

Techninis įvertinimas

By Trading Central

14.1 / 14.44Palaikymas ir pasipriešinimas

Trumpalaikis periodas

Bearish Evidence

Vidutinės trukmės periodas

Strong Bearish Evidence

Ilgalaikis periodas

Bearish Evidence

Rinkos nuotaikos

By Acuity

161 / 351 reitingas Sveikatos priežiūra

Naujienos nuotaikos

Neutral

Svyravimai

Žemiau vidurkio

Naujienų apimtis (RCV)

Vidutinis

Finansinės naujienos

Pardavimo ir administravimo išlaidos

Veiklos sąnaudos

Ikimokestinis pelnas

Pardavimai

Pardavimo savikaina

Bendrasis pelnas iš pardavimo

Skolų palūkanų išlaidos

EBITDA

Veiklos pelnas

$

Apie bendrovę Inmode Ltd

InMode Ltd. designs, develops, manufactures, and markets minimally invasive aesthetic medical products based on its proprietary radiofrequency assisted lipolysis and deep subdermal fractional radiofrequency technologies in the United States and internationally. The company offers minimally invasive aesthetic medical products for various procedures, such as liposuction with simultaneous skin tightening, body and face contouring, and ablative skin rejuvenation treatments, as well as for use in women's health conditions and procedures. It also designs, develops, manufactures, and markets non-invasive medical aesthetic products that target an array of procedures, including permanent hair reduction, facial skin rejuvenation, wrinkle reduction, cellulite treatment, skin appearance and texture, and superficial benign vascular and pigmented lesions, as well as hands-free medical aesthetic products that target a range of procedures, such as skin tightening, fat reduction, and muscle stimulation. The company was formerly known as Invasix Ltd. and changed its name to InMode Ltd. in November 2017. InMode Ltd. was incorporated in 2008 and is headquartered in Yokne'am, Israel.
help-icon Live chat